Back to Peptides
Fat LossMedium Risk

Tirzepatide

Also known as: Mounjaro, Zepbound, Dual GLP-1, GLP-1/GIP

Half-life:
~5 days (once-weekly dosing)

Administration Routes

subcutaneous
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.

Tirzepatide is a once-weekly injectable dual agonist of GLP-1 and GIP receptors, FDA approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Clinical trials demonstrate weight reductions exceeding those seen with semaglutide in head-to-head comparisons. Compounded formulations are offered by telehealth and functional medicine providers across the US. It represents the current clinical frontier in pharmacological weight management.

Primary Research Areas

  • fat_loss

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Providers Offering Tirzepatide